Derazantinib
| CAS No. | 1234356-69-4 | Cat. No. | BCP29103 |
| Name | Derazantinib | ||
| Synonyms | ARQ087;ARQ-087;ARQ 087; | ||
| Formula | C29H29FN4O | M. Wt | 468.57 |
| Description | Derazantinib, also known as ARQ-087, is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. FGFR inhibitor ARQ 087 binds to and potently inhibits the activity of FGFR subtypes 1, 2 and 3. This may result in the inhibition of FGFR-mediated signal transduction pathways, tumor cell proliferation, tumor angiogenesis and tumor cell death in FGFR-overexpressing tumor cells. FGFR, a receptor tyrosine kinase, is upregulated in many tumor cell types and plays a key role in tumor cellular proliferation, differentiation, angiogenesis and survival. | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase | ||
| Targets | FGFR | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.